Fig. 2
From: “Oil-soluble” reversed lipid nanoparticles for oral insulin delivery
a The ORLN-peptide recombinant human insulin (PHI) formulations. Right: the Tyndall phenomenon in a pure oil solution. Left: the ORLN-PHI solution was transparent and distinct from a simple mixture of pure oil and insulin powder. b Light transmittance of ORLN-PHI formulations with different phospholipid (PC)/PHI ratios. c Size distribution of ORLN-PHI (PC/PHI ratio 500:1) by dynamic light scattering. d Transmission electron micrograph of ORLN-PHI (PC/PHI ratio 500:1)